2.Nutrition Therapy in Crohn’s Disease
Yuanyuan GE ; Yi LI ; Jianfeng GONG ; Zhen GUO ; Lei CAO ; Weiming ZHU ; Jieshou LI
Chinese Journal of Gastroenterology 2016;21(12):711-713
Nutrition therapy is an important part of the treatment of Crohn’s disease(CD),which plays an important role in correcting malnutrition,inducing disease remission,and for the perioperative management. Nutrition therapy, especially enteral nutrition(EN),has been studied for its effect on CD. We have long been focusing on the use of nutrition therapy in the treatment of CD,especially the use of EN in the perioperative management of CD. Here,we reviewed the indications,effects,endpoints and the underlying mechanisms of preoperative nutrition therapy,through which we hope can shed light on improving the optimization of preoperative management as well as the standardization of preoperative nutrition therapy in CD.
3.Expression of indoleamine 2, 3-dioxygenase in condyloma acuminatum lesions
Zhen XIE ; Yuanhan CHEN ; Siyu WANG ; Huiying WAN ; Hua LEI ; Ge YANG ; Zhaochun LIN
Chinese Journal of Dermatology 2017;50(5):337-340
Objective To measure the expression of indoleamine 2, 3-dioxygenase(IDO)in condy-loma acuminatum (CA) lesions, and to evaluate its ability to locally metabolize tryptophan. Methods Immunohistochemical study was performed to observe the protein expression of IDO in skin lesions of patients with CA, and count the number of IDO-positive cells. Immunofluorescence assay was conducted to estimate the relationship between IDO-positive cells and dendritic cells. Epidermal cells and keratinocytes were isolated from warts of 30 patients with CA and prepuces of 11 healthy controls respectively, and both in vitro incubated with tryptophan solution for 4 hours. Then, high-performance liquid chromatography (HPLC)was performed to detect the level of tryptophan metabolite, kynurenine, in the culture supernatant of the above cells, which could reflect the ability of epidermal cells to metabolize tryptophan. Results Rare IDO-positive cells were found in the normal skin, but a lot of IDO-positive cells gathered in the epidermis of the wart tissues. The IDO-positive cell/total cell ratio was significantly higher in the wart tissues than in the normal skin(48.3%± 15.4%vs. 5.2%± 2.4%, P<0.05). The fluorescence signals of IDO-positive cells and CD1a-positive Langerhans cells were not overlapped with each other, suggesting that IDO-positive cells were derived from epidermal cells of the wart tissues. Compared with the keratinocytes from the healthy skin, the epidermal cells from warts had a stronger ability to metabolize tryptophan in vitro. Conclusion A large number of IDO-positive cells exist in CA warts, and may be involved in occurrence of CA.
4. Therapeutic response of radiosynovectomy with p-32 colloid in 326 patients with hemophilic arthropathy
Zhen WANG ; Yin ZHANG ; Yinghui GE ; Huijuan LIU ; Yanhui LIU ; Jiajun ZHAO ; Yingcong DOU ; Pingchong LEI
Chinese Journal of Hematology 2017;38(1):39-43
Objective:
To observe the therapeutic response of radiosynovectomy with p-32 colloid on hemophilic arthropathy, and to assess the effects of radiosynovectomy with Denver Score on hemophilic arthritis staging.
Methods:
Radiosynovectomy with p-32 colloid was performed on 326 hemophilic arthritis patients (405 joints) , and recorded bleeding before and after treatment. The MRI performance of 102 joints was evaluated by using Denver scoring system, then was divided into 0-6 and 7-10 groups. Finally, the differences between 2 groups were analyzed.
Results:
Average pain score of all hemophilic arthritis patients at 6 months, 1, 2 and 3 years post treatment decreased from 3.2±2.4 (
5.Upregulation and biological function of transmembrane protein 119 in osteosarcoma.
Zhen Huan JIANG ; Jun PENG ; Hui Lin YANG ; Xing Li FU ; Jin Zhi WANG ; Lei LIU ; Jian Nong JIANG ; Yong Fei TAN ; Zhi Jun GE
Experimental & Molecular Medicine 2017;49(5):e329-
Osteosarcoma is suggested to be caused by genetic and molecular alterations that disrupt osteoblast differentiation. Recent studies have reported that transmembrane protein 119 (TMEM119) contributes to osteoblast differentiation and bone development. However, the level of TMEM119 expression and its roles in osteosarcoma have not yet been elucidated. In the present study, TMEM119 mRNA and protein expression was found to be up-regulated in osteosarcoma compared with normal bone cyst tissues. The level of TMEM119 protein expression was strongly associated with tumor size, clinical stage, distant metastasis and overall survival time. Moreover, gene set enrichment analysis (GSEA) of the Gene Expression Omnibus (GEO) GSE42352 dataset revealed TMEM119 expression in osteosarcoma tissues to be positively correlated with cell cycle, apoptosis, metastasis and TGF-β signaling. We then knocked down TMEM119 expression in U2OS and MG63 cells using small interfering RNA, which revealed that downregulation of TMEM119 could inhibit the proliferation of osteosarcoma cells by inducing cell cycle arrest in G0/G1 phase and apoptosis. We also found that TMEM119 knockdown significantly inhibited cell migration and invasion, and decreased the expression of TGF-β pathway-related factors (BMP2, BMP7 and TGF-β). TGF-β application rescued the inhibitory effects of TMEM119 knockdown on osteosarcoma cell migration and invasion. Further in vitro experiments with a TGF-β inhibitor (SB431542) or BMP inhibitor (dorsomorphin) suggested that TMEM119 significantly promotes cell migration and invasion, partly through TGF-β/BMP signaling. In conclusion, our data support the notion that TMEM119 contributes to the proliferation, migration and invasion of osteosarcoma cells, and functions as an oncogene in osteosarcoma.
Apoptosis
;
Bone Cysts
;
Bone Development
;
Cell Cycle
;
Cell Cycle Checkpoints
;
Cell Movement
;
Dataset
;
Down-Regulation
;
Gene Expression
;
In Vitro Techniques
;
Neoplasm Metastasis
;
Oncogenes
;
Osteoblasts
;
Osteosarcoma*
;
RNA, Messenger
;
RNA, Small Interfering
;
Up-Regulation*
6.Cloning of human angiogenesis inhibitor METH1 and its expression in mammalian cells.
Yang ZHANG ; Kai-hua LU ; Shu-zhong GUO ; Ge SONG ; Guo-rong YANG ; Zhen WANG ; Yong-hong LEI
Chinese Journal of Plastic Surgery 2004;20(3):225-227
OBJECTIVETo get the full length of human METH1 cDNA and express it steadily in mammalian cell stably.
METHODSMETH1 was amplified by RT-PCR, and cloned into pCDNA3.0 after confirmed by sequence analysis. HepG2 cells were transfected by Lipofectamine reagent and then selected in medium with G418. The expression level of METH1 was detected by RT-PCR and Western blot.
RESULTSMETH1 with expected length was effectively amplified, and completely matched the published sequence of encoding mature peptide [GI:5725505] as shown by sequence analysis. Eukaryotic vector expressing METH1 was obtained by gene cloning, cells expressing METH1 was got by selection with G418 at 3 weeks after transfection. RT-PCR and Western blot showed high level expression of METH1.
CONCLUSIONFull length of human METH1 gene is cloned successfully and expressed in HepG2 steadily, The results set up a basis for the study of effects of METH1 on hypertrophic scar angiogenesis.
ADAM Proteins ; ADAMTS1 Protein ; Angiogenesis Inhibitors ; genetics ; metabolism ; Blotting, Western ; Cell Line, Tumor ; Cloning, Molecular ; DNA, Complementary ; genetics ; metabolism ; Disintegrins ; genetics ; metabolism ; Humans ; Metalloendopeptidases ; genetics ; metabolism ; Reverse Transcriptase Polymerase Chain Reaction ; Transfection ; methods
7.Transplantation of autologous bone marrow mononuclear cells on patients with idiopathic dilated cardiomyopathy: early results on effect and security.
Rong-chong HUANG ; Kang YAO ; Yan-lin LI ; Yi-qi ZHANG ; Shi-kun XU ; Hong-yu SHI ; Cui-zhen PAN ; Shan YANG ; Shao-heng ZHANG ; Lei GE ; Yu-hong NIU ; Feng ZHANG ; Ju-ying QIAN ; Yun-zeng ZOU ; Jun-Bo GE
Chinese Journal of Cardiology 2006;34(2):111-113
OBJECTIVEThe aim of this study is to identify short-term result of cell transplantation in idiopathic dilated cardiomyopathy (IDC) patients who were treated by intracoronary transplantation of autologous mononuclear bone marrow cells (BMCs) in addition to standard therapy.
METHODSBased on given standard therapy, eighteen patients with idiopathic dilated cardiomyopathy were enrolled and divided into transplantation group and control group. The clinical characteristics of two groups were comparable. Among these patients, 10 patients were performed percutaneous coronary autologous BMCs transplantation. Blood routine test, hepatic function, renal function, glucose, triglyceride (TG), cholesterol, low density cholesterol (LDL), high density cholesterol (HDL), uric acid (UA) and high sensitive C-reactive protein (hsCRP) were measured at the time point of pre-operation and some time after transplantation. All patients were monitored under ultrasonic cardiography, Holter, six-minute-walk test and magnetic resonance imaging over a period of at least 6 months. Annual hospital days were recorded during two-year follow-up.
RESULTSBlood routine test, hepatic function, renal function, glucose, TG, cholesterol, LDL, HDL, UA and hsCRP had no significant differences among 48 hours, 3 months and 6 months after transplantation compared with control and pre-transplantation (P > 0.05). Six-minute-walk distance elevated significantly six months after BMCs transplantation compared with control and pre-transplantation [(494.3 +/- 62.8) m vs (307.2 +/- 75.0) m, (321.5 +/- 63.7) m, P < 0.05]. Left ventricular ejection fraction (LVEF) and the sizes of LVEDd had no significant changes compared with that of control and pre-transplantation (P > 0.05). Myocardium lesion area measured by (MRI) seemed decrease in transplantation group compared with that of control and pre-operation [(4.96 +/- 0.47) cm(2) vs (5.12 +/- 0.54) cm(2), (5.02 +/- 0.39) cm(2), P > 0.05], but there was no significance. None of proarrhythmias and side effects had been observed around transplantation and 2 years follow-up. There was no significant difference in survival between two groups in 2 years follow-up. Interestingly, annual hospital day in BMCs transplantation patients was significantly shorter than that in control group [(30.2 +/- 11.2) d vs (43.6 +/- 9.8) d, P < 0.05].
CONCLUSIONSAutologous bone marrow mononuclear cells transplantation can prolong six-minute-walk, decrease re-hospitalization rate, elevate exercise ability and help to improve cardiac function in patients with IDC. In addition, it was demonstrated that cell transplantation is safe.
Bone Marrow Transplantation ; Cardiomyopathy, Dilated ; surgery ; therapy ; Humans ; Transplantation, Autologous ; Treatment Outcome
8.Protective antitumor immunity induced by tumor cell lysates conjugated with diphtheria toxin and adjuvant epitope in mouse breast tumor models.
Ze-Yu WANG ; Yun XING ; Bin LIU ; Lei LU ; Xiao HUANG ; Chi-Yu GE ; Wen-Jun YAO ; Mao-Lei XU ; Zhen-Qiu GAO ; Rong-Yue CAO ; Jie WU ; Tai-Ming LI ; Jing-Jing LIU
Chinese Journal of Cancer 2012;31(6):295-305
Cancer cell vaccine-based immunotherapy has received increasing interest in many clinical trials involving patients with breast cancer. Combining with appropriate adjuvants can enhance the weak immunogenic properties of tumor cell lysates (TCL). In this study, diphtheria toxin (DT) and two tandem repeats of mycobacterial heat shock protein 70 (mHSP70) fragment 407-426 (M2) were conjugated to TCL with glutaraldehyde, and the constructed cancer cell vaccine was named DT-TCL-M2. Subcutaneous injection of DT-TCL-M2 in mice effectively elicited tumor-specific polyclonal immune responses, including humoral and cellular immune responses. High levels of antibodies against TCL were detected in the serum of immunized mice with ELISA and verified with Western blot analyses. The splenocytes from immunized mice showed potent cytotoxicity on Ehrlich ascites carcinoma cells. Moreover, the protective antitumor immunity induced by DT-TCL-M2 inhibited tumor growth in a mouse breast tumor model. DT-TCL-M2 also attenuated tumor-induced angiogenesis and slowed tumor growth in a mouse intradermal tumor model. These findings demonstrate that TCL conjugated with appropriate adjuvants induced effective antitumor immunity in vivo. Improvements in potency could further make cancer cell vaccines a useful and safe method for preventing cancer recurrence after resection.
Adjuvants, Immunologic
;
Animals
;
Bacterial Proteins
;
genetics
;
immunology
;
Cancer Vaccines
;
immunology
;
Carcinoma, Ehrlich Tumor
;
immunology
;
pathology
;
Cell Line, Tumor
;
Cell Proliferation
;
Diphtheria Toxin
;
genetics
;
immunology
;
Female
;
HSP70 Heat-Shock Proteins
;
genetics
;
immunology
;
Immunoglobulin G
;
immunology
;
Immunotherapy
;
Mice
;
Neovascularization, Pathologic
;
Peptide Fragments
;
genetics
;
immunology
;
Recombinant Fusion Proteins
;
genetics
;
immunology
;
T-Lymphocytes, Cytotoxic
;
immunology
;
Tandem Repeat Sequences
9.Analyse related factors of impact and prognosis of 73 cases of severe hepatitis.
Jun-Mei ZHAO ; Lu ZHANG ; Qing-Wei DU ; Cai-Qin MU ; Yv-Lian REN ; Lei-Ping HU ; Ge SHEN ; Li-Wei ZHUANG ; Yao LU ; Guo-Hua QIU ; Qing-Feng SUN ; Yun-Zhong WU ; Min YANG ; Ming-Hui LI ; Yao XIE ; Jun CHENG ; Dao-Zhen XU
Chinese Journal of Experimental and Clinical Virology 2013;27(5):366-369
OBJECTIVEA retrospective study was conducted to investigate the clinical features and prognostic factors of 73 cases of severe hepatitis.
METHODSTo summarize clinical features of 73 cases of severe hepatitis, grouping by etiology and pathogenesis. A retrospective analysis was performed to evaluate the relationship between biochemical characteristics (liver function, renal function, electrolytes, PTA, etc) and complications (hepatic encephalopathy, upper gastrointestinal bleeding, hepatorenal syndrome, ascites, abdominal infections, etc) and prognosis.
RESULTS(1) HBV infection alone accounted for 65.75%. Alcoholic liver disease, drug-induced liver injury, hepatitis E, autoimmune hepatitis, overlapping causes and other factors were five cases (6.85%), six cases (8.22%), two cases (2.74%), two cases (2.74%), seven cases (9.59%) and three cases (4.11%) respectively. According to the incidence rate, severity and underlying liver condition, subacute hepatitis, cases based on chronic hepatitis and on cirrhosis were 12 cases (16.43%), 11 cases (15.07%), 50 cases (68.49%) respectively. Clinical manifestations with or without hepatic encephalopathy accounted for 58.90% or 41.10%. (2) The highest mortality of severe hepatitis was alcoholic liver disease and patients on the basis of overlapping factors (66.67%), followed by autoimmune liver disease (50%). The mortality of HBV-related hepatitis was 18.75%. Overall mortality of 73 cases of severe hepatitis was 28.77%, of which cirrhosis group was higher than non-cirrhotic group (40% vs 4.3%, P = 0.002). The difference was statistically significant. Patients without hepatic encephalopathy had lower mortality than with hepatic encephalopathy (3.33% vs 46.51%). The mortality of patients with hepatic encephalopathy Stage III and IV was 72.73%. (3) Independent samples t test filtered nine factors associated with death, namely cirrhosis, upper gastrointestinal bleeding, hepatic encephalopathy, hepatorenal syndrome, serum creatinine, total bilirubin (TBIL), direct bilirubin (DBIL), albumin (ALB) and serum sodium. The results of multivariate conditional logistic regression analysis indicated that hepatic encephalopathy, serum creatinine levels were risk factors for death, whereas ALB as a protective factor.
CONCLUSIONHepatic encephalopathy, serum creatinine levels were risk factors for severe hepatitis death, But ALB was protective factor. Nucleotide analogs using was the main reason why the mortality of hepatitis B was as low as 18.75%.
Adult ; Aged ; Female ; Hepatitis ; complications ; mortality ; pathology ; virology ; Hepatitis B virus ; genetics ; isolation & purification ; Humans ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Risk Factors
10.Summary of 32 patients with cardiac syndrome X treated by TCM therapy of regulating qi relieving chest stuffiness and promoting blood circulation.
Jing-Yuan MAO ; Yong-Bin GE ; Heng-He WANG ; Qiang WANG ; Yun ZHANG ; Dong-Ling YU ; Yu ZHANG ; Qi HUANG ; Zhi-Qiang ZHAO ; Gui-Feng ZHAO ; Zhan-Wu WANG ; Xue-Peng MA ; Zhen-Peng ZHANG ; Ming LI ; Lei SHAO ; Chun-Yan ZHAO
Chinese journal of integrative medicine 2007;13(1):17-21
OBJECTIVETo evaluate the clinical effect of Liqi Kuanxiong Huoxue method LKH, traditional Chinese medicine, TCM therapeutic method for regulating qi, relieving chest stuffiness and promoting blood circulation) in treating patients with cardiac syndrome X (CSX).
METHODSThe prospective, non-randomized controlled study was conducted on 51 selected patients with CSX, who were non-randomly assigned to 2 groups, the treated group treated with LKH in addition to the conventional treatment (32 patients), and the control group treated with conventional treatment (19 patients) like nitrate, diltiazem hydrochloride, etc. The treatment course was 14 days. The changes of such symptoms as angina pectoris, TCM syndrome and indexes of treadmill exercise test before and after treatment were observed.
RESULTSAfter treatment, such symptoms as chest pain and stuffy feeling and palpitation in the treated group were improved more than those in the control group (P<0.05); the total effective rate on angina pectoris and TCM syndrome in the treated group was better than that in the control group (P<0.05). The treadmill exercise test showed that the maximal metabolic equivalent (Max MET), the time of angina onset and ST segment depression by 0.1 mV were obviously improved after treatment in both groups, but the improvement in the treated group was better than that in the control group respectively (P<0.05).
CONCLUSIONThe LKH method could reduce the frequency of angina attacks and improve the clinical condition of patients with CSX.
Blood Circulation ; Drug Combinations ; Drugs, Chinese Herbal ; adverse effects ; therapeutic use ; Exercise Test ; Female ; Humans ; Male ; Microvascular Angina ; diagnosis ; physiopathology ; therapy ; Middle Aged ; Qi ; Thorax ; physiopathology ; Treatment Outcome